Semaglutide was approved by the FDA to treat weight loss for individuals with a BMI of 30 or higher and individuals with an elevated BMI who also have a weight-related comorbidity (high blood pressure, high cholesterol, fatty liver disease, etc.)
This is one of its main advantages over GLP-1 injectable medications
It helps control blood sugar, lowers cardiovascular risks, and slows the progression of kidney disease
Cardiovascular Protection Independent of Glucose Control One of the most intriguing findings from the SELECT trial involves semaglutide's mechanism of cardiovascular benefit
Key highlights Semaglutide is supposed to reduce your appetite within 1-4 weeks of starting the medication, but its normal to feel still hungry while your body gets used to the medication
Semaglutide is a glucagon-like peptide-1 (GLP-1) drug